The information provided on this website is for educational purpose and not to be considered as investing or trading advice.
The investment and trading has to be done on sole discretion and www.daytradingshares.com or any person related to this site Should not be held responsible for the outcome.
Copyright © 2007-2017, www.daytradingshares.com. All Rights Reserved.
9 Stocks to pick for the year 2017
22 feb 2017
Earning is a big factor which can influence stock prices. The fear which clouded Indian markets in the name of demonetisation and Trumponomics seems to have receded.
Hindalco Industries, an Aditya Birla Group company, has reported a net profit of Rs 321 crore in the December quarter against a net loss of Rs 33 crore in the same period last year.
A sharp increase in aluminium realisation and tight control on expenses helped the company post a better performance, despite weak demand for copper and lower by-product realisations.
As per the management of the company, its revenue growth comes out of its backlog; growth in volumes comes from small and medium sized orders primarily in the railways and energy transmission segment. Moreover, the growth of the company would depend on large public tenders in these segments.
During the quarter ended December 2016, the company has maintained the net interest margin (NIM) target of 2.95-3.05 per cent, despite the expectation of a decline in loan yield of 14-15 in Q4FY2017.
The decline in the cost of funds is expected to support margins of the company. The company has targeted loan growth in the range of 16-18 per cent. The proportion of project finance portfolio is expected to increase to 14-15 per cent from existing 11.5 per cent in Q3FY17.
Auto component maker Motherson Sumi Systems has reported a 28.24 per cent increase in consolidated net profit at Rs 547.32 crore in the third quarter ended December.
The company has shown exemplary growth in all areas and has achieved highest-ever revenues and margins in a quarter.
Power Grid Corporation
For the quarter ended December 16, net sales of Power Grid stood at Rs 6629.76 crore up by 23 per cent on a year-on-year (YoY) basis. Net revenue from transmission business, which constitutes around 95 per cent of total revenue, was up 22 per cent to Rs 6,206.84 crore.
The company maintained the capital expenditure (capex) momentum despite the slowdown in the broader economy.
Indian Oil Corporation:
Indian Oil posted a net profit of Rs 15,386 crore for the nine months ended 31st December 2016 as compared to net profit of Rs 9,236 crore during the corresponding period of the previous year.
The company expects to ramp up capacity utilisation of Paradip refinery to 95 per cent by the FY17 end. The company has capex plans of Rs 19,600 crore for FY'18 and Rs 25,000 crore for FY19.
During Q3FY17, it has registered 28 per cent growth in its net profit to Rs 84.28 crore while its sales for the period was lower by 12 per cent to Rs 325.01 crore. Strong growth at bottom-line despite lower sales is largely due to 1,180 bps jump in operating profit margin to 24.9 per cent which wiped out the impact of lower sales and facilitated strong 68 per cent growth in operating profit to Rs 80.91 crore.
Moreover, it has a healthy balance sheet with strong cash balance and its order inflows have improved in the last one-two years. The company has a healthy mix of domestic and overseas orders.
State-owned gas utility GAIL India reported 46 per cent rise in its third-quarter net profit on the back of turnaround in petrochemical business.
The company also registered growth in physical performance in all segments - petrochemical sales were up by 8 per cent, liquid hydrocarbon by 4 per cent and natural gas marketing and transmission volumes were up by 3 per cent and 2 per cent respectively.
On a consolidated basis, Granules India net profit rose 33.8 per cent to Rs 39.06 crore on 10.6 per cent growth in net sales to Rs 359.24 crore in Q3 December 2016 over Q3 December 2015.
The company is aggressively pursuing completion of active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI) expansion plans and the introduction of new products following appropriate filings strategy.